首页 > 市场调查报告书 > 医疗设备

医学影像诊断分子呈像/呈影剂

Gadoquatrane市场规模、份额和成长分析（按应用程式、最终用户和地区划分）—2026-2033年产业预测

市场调查报告书

商品编码

1907437

Gadoquatrane市场规模、份额和成长分析（按应用程式、最终用户和地区划分）—2026-2033年产业预测

Gadoquatrane Market Size, Share, and Growth Analysis, By Application (Screening, Diagnosis), By End User (Hospital, Diagnostic Centres), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，Gadoquatrane市场规模将达到 20 亿美元，到 2025 年将达到 21 亿美元，到 2033 年将达到 31.3 亿美元，在预测期（2026-2033 年）内复合年增长率为 5.1%。

市场趋势表明，磁振造影（MRI）造影剂市场正呈现显着成长态势，这主要得益于新型高效能大环钆基造影剂（mGBCA）—钆喹啉（Gadoquatrane）的问世。Gadoquatrane具有卓越的理化性质，包括高弛豫率、稳定性和极低的蛋白质结合率，同时其药物动力学特征与现有mGBCA相似，表现为快速的细胞外分布和有效的肾臟排泄。这种不断增长的需求主要源于癌症、神经系统疾病和心血管疾病等慢性疾病发生率的上升。先进的影像技术对于这些疾病的精准诊断和治疗方案製定至关重要。此外，人口老化以及人们对非侵入性诊断方法的日益青睐预计也将显着推动MRI造影剂市场的发展。

Gadoquatrane市场驱动因素

Gadoquatrane市场主要受磁振造影（MRI）造影剂强劲需求的推动，而这又受到慢性病发病率上升、人口老化以及人们日益倾向于非侵入性诊断方法等因素的影响。此外，技术进步和医疗费用支出的成长也促进了这一成长趋势。钆基造影剂（GBCA）因其在造影增强磁振造影（CE-MRI）中的有效性而备受认可，并已在全球数百万例检查中使用。 CE-MRI卓越的影像能力涵盖多个医学领域，有助于改善诊断和疾病管理，这使得Gadoquatrane成为未来临床应用领域极具潜力的候选药物。

Gadoquatrane市场的限制因素

多种因素限制了造影造影（MRI）造影剂的需求，并导致其价格下降。这些造影剂的高成本以及新出现的安全性问题是造成此趋势的关键因素。此外，替代诊断方法的兴起以及以价值为导向的医疗模式的转变进一步加剧了这些限制。非造影MRI技术的进步提高了准确性和效率，从而减少了对造影剂的需求。随着医疗成本的不断上涨，患者和医疗服务提供者可能会更倾向于选择更具成本效益的非造影方案。虽然造影剂通常被认为是安全的，但对潜在副作用的担忧可能会导致一些人完全避免造影显影剂，这可能会影响市场需求。

Gadoquatrane市场趋势

由于钆基造影剂相关的健康问题，特别是肾功能受损患者出现严重副作用风险增加，Gadoquatrane市场正经历重大变革。这推动了对替代品的需求，尤其是无钆造影剂，其中氧化铁奈米颗粒和锰基溶液作为极具潜力的候选药物脱颖而出。对病患安全的关注以及对创新诊断影像解决方案的追求，正推动对这些新型造影剂的投资和研发，迫使製造商优先开发更安全、更有效的诊断造影剂。这一趋势凸显了诊断成像领域变革时期，并强调了该行业致力于改善患者预后的决心。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Bayer AG（Germany）
GE Healthcare（United States）
Guerbet Group（France）
Bracco Imaging SpA（Italy）
Lantheus Medical Imaging, Inc.（United States）
Daiichi Sankyo Company, Limited（Japan）
Spago Nanomedical AB（Sweden）
Trivitron Healthcare（India）
Jodas Expoim Pvt. Ltd.（India）
CMR Naviscan Corporation（United States）
Subhra Pharma Pvt. Ltd.（India）
Macrocyclics, Inc.（United States）
iMax Diagnostic Imaging Limited（China）
Beijing Beilu Pharmaceutical Co., Ltd.（China）
Jiangsu Hengrui Medicine Co., Ltd.（China）
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.（China）
Yantai Dongcheng Pharmaceutical Group Co., Ltd.（China）
Sanochemia Pharmazeutika AG（Austria）
Medtronic plc（Ireland）

结论与建议

简介目录

Product Code: SQMIG35I2135

Gadoquatrane Market size was valued at USD 2.0 Billion in 2024 and is poised to grow from USD 2.1 Billion in 2025 to USD 3.13 Billion by 2033, growing at a CAGR of 5.1% during the forecast period (2026-2033).

Market insights suggest a substantial growth trajectory for MRI contrast media agents, particularly with the introduction of gadoquatrane, a novel, highly potent macrocyclic gadolinium-based contrast agent (mGBCA). Gadoquatrane offers exceptional physicochemical properties, including high relaxivity and stability, coupled with negligible protein binding, mirroring the pharmacokinetic profiles of existing mGBCAs characterized by rapid extracellular distribution and effective renal excretion. This growth in demand is primarily fueled by the rising incidence of chronic conditions such as cancer, neurological disorders, and cardiovascular diseases, all of which necessitate advanced imaging techniques for accurate diagnosis and treatment planning. Furthermore, an aging population and a growing preference for non-invasive diagnostic methods are anticipated to bolster the market for MRI contrast agents significantly.

Top-down and bottom-up approaches were used to estimate and validate the size of the Gadoquatrane market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Gadoquatrane Market Segments Analysis

Global Gadoquatrane Market is segmented by Application, End User and region. Based on Application, the market is segmented into Screening and Diagnosis. Based on End User, the market is segmented into Hospital, Diagnostic Centres, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Gadoquatrane Market

The Gadoquatrane market is being driven by a robust demand for MRI contrast media agents, fueled by factors such as the rising prevalence of chronic diseases, an aging population, and the growing preference for non-invasive diagnostic procedures. Additionally, advancements in technology and increased healthcare spending are contributing to this upward trend. Gadolinium-based contrast agents (GBCAs) have long been recognized for their effectiveness in contrast-enhanced magnetic resonance imaging (CE-MRI), with millions of procedures utilizing these agents globally. The superior imaging capabilities offered by CE-MRI span various medical fields, enhancing diagnosis and disease management, which positions Gadoquatrane as a promising candidate for future clinical applications.

Restraints in the Gadoquatrane Market

Several factors can limit the demand and contribute to the decrease in prices for MRI contrast media agents. High costs associated with these agents, along with emerging safety concerns, play a significant role in this dynamic. Additionally, the rise of alternative diagnostic methods and a shift towards value-based healthcare further amplify these constraints. Advances in non-contrast MRI techniques are enhancing precision and efficiency, thereby reducing the necessity for contrast agents. Patients and healthcare providers may prefer more cost-effective non-contrast options as healthcare expenses rise. Although generally considered safe, awareness of potential side effects may prompt some to avoid contrast agents altogether, impacting market demand.

Market Trends of the Gadoquatrane Market

The Gadoquatrane market is experiencing a notable shift driven by rising health concerns associated with gadolinium-based contrast agents, particularly their potential severe side effects in patients with compromised kidney function. This has catalyzed a growing demand for alternatives, specifically gadolinium-free contrast agents, with iron oxide nanoparticles and manganese-based solutions emerging as promising contenders. The focus on patient safety and the quest for innovative imaging solutions are steering investment and research towards these novel agents, compelling manufacturers to prioritize the development of safer, effective diagnostics. This trend highlights a transformative phase in the imaging landscape, emphasizing the industry's commitment to enhancing patient outcomes.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies

Global Gadoquatrane Market Size by Application & CAGR (2026-2033)

Market Overview
Screening
Diagnosis

Global Gadoquatrane Market Size by End User & CAGR (2026-2033)

Market Overview
Hospital
Diagnostic Centres
Specialty Clinics
Others

Global Gadoquatrane Market Size & CAGR (2026-2033)

North America (Application, End User)
- US
- Canada
Europe (Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guerbet Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bracco Imaging S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lantheus Medical Imaging, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Spago Nanomedical AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Trivitron Healthcare (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jodas Expoim Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CMR Naviscan Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Subhra Pharma Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Macrocyclics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
iMax Diagnostic Imaging Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beijing Beilu Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jiangsu Hengrui Medicine Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanochemia Pharmazeutika AG (Austria)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments